Rare
lephants
Screener
Toggle theme
Telix Pharmaceuticals Limited
TLPPF
·
Healthcare, Drug Manufacturers - General, Australia
Financial Statements
Profitability
Balance Sheet
Cash Flow
Price Ratios
Share-Based Metrics
Valuation
Cash Flow History
Net Cash Flow Breakdown
Net Cash Flow
Cash Flow
›
Net Cash Flow Breakdown
Net Cash Flow Breakdown
Chart
Table
FY2024
FY2023
Total Cash from Operations:
$463.4M
Line Item
Value
% of Total
Capital Expenditures
$9.1M
2.0%
Other Investing
$77.6M
16.7%
Working Capital
$19.1M
4.1%
Net Cash Flow
$357.6M
77.2%
Download CSV
